Cross-protective efficacy of a bovine viral diarrhea virus (BVDV) type 1 vaccine against BVDV type 2 challenge
Cross-protective efficacy of a bovine viral diarrhea virus (BVDV) type 1 vaccine against BVDV type 2 challenge
复制标题
DOI：
10.1016/s0264-410x(98)00329-6
复制
发表时间：
1999-03-05
期刊：
影响因子：
5.5
通讯作者：
Leyh, R
中科院分区：
文献类型：
--
作者：
Dean, HJ;Leyh, R
牛病毒性腹泻病毒(BVDV)的一种新基因型，命名为BVDV 2型(BVDV 2)，已在Hold流行。BVDV 2毒株在抗原性上与目前可用的BVDV 1基因型疫苗毒株不同，这引发了人们对这些疫苗对抗BVDV 2挑战的交叉保护的担忧。为确定BVDV1WRL株修饰活病毒疫苗(BVDV1(WRL))的交叉保护效果，对BVDV1和BVDV2特异性血清学应答的相对大小和持续时间以及对BVDV2攻击的保护作用进行了两项研究。在第一项研究中，27头小母牛接种了疫苗(13I.M.14头)，13头母牛接种阴性对照疫苗。免疫母牛的血清中和了BVDV I和BVDV 2毒株。BVDV I和BVDV 2的血清学应答的演变和持续时间相似，BVDV 2的抗体滴度在单次免疫后至少105天持续存在。在另一项单独的研究中，17头小牛接种了疫苗(9I.M.和8头S.C.)，II头犊牛作为未接种的对照。接种疫苗后大约7个月，用BVDV-2 890分离株经鼻攻击小牛。与对照组相比，接种组的疾病和发热临床症状显著减少。接种疫苗消除了87%的牛鼻病毒脱落，完全预防了病毒血症和白细胞减少症。这些数据表明，BVDV I(WRL)MLV疫苗在刺激BVDV 2的长期特异性血清学反应、保护BVDV 2攻击和减少或消除有助于BVDV 2在畜群中传播的病毒脱落方面具有实用价值。(C)1999由爱思唯尔科学有限公司出版。版权所有。
A new genotype of bovine viral diarrhea virus (BVDV), designated BVDV type 2 (BVDV 2), has become prevalent in the held. BVDV 2 strains are antigenically distinct from currently available Vaccine strains of the BVDV 1 genotype, raising concerns about cross-protection of these Vaccines against BVDV 2 challenge. To determine cross-protective efficacy of a modified-live virus (MLV) Vaccine containing BVDV 1 strain WRL (BVDV 1(WRL)), two studies were conducted in which the relative magnitude and duration of BVDV 1- and BVDV 2-specific serologic responses and protection against BVDV 2 challenge were determined. For the first study, 27 heifers were vaccinated (13 i.m. and 14 s.c.), while 13 heifers received negative control vaccine. Serum from the vaccinated heifers neutralized both BVDV I and BVDV 2 strains. The evolution and duration of BVDV I and BVDV 2 serologic responses were comparable, and antibody titers to BVDV 2 persisted through at least 105 days post-single vaccination. In a second, separate study, 17 calves were vaccinated (9 i.m. and 8 s.c.), and II calves were held as unvaccinated controls. Approximately seven months following vaccination, the calves were challenged intranasally with the 890 isolate of BVDV 2. Clinical signs of disease and fever were significantly reduced in vaccinates in comparison with controls. Vaccination eliminated nasal virus shedding in 87% of cattle and completely prevented viremia and leukopenia. These data indicate utility of BVDV I(WRL) MLV vaccine in stimulation of long-term BVDV 2-specific serologic responses, protection against BVDV 2 challenge and reduction or elimination of virus shedding which can contribute to spread of BVDV 2 in herds. (C) 1999 Published by Elsevier Science Ltd. All rights reserved.